JP2023500895A - Ｎｐｙ２受容体アゴニスト - Google Patents

Ｎｐｙ２受容体アゴニスト Download PDF

Info

Publication number
JP2023500895A
JP2023500895A JP2022526028A JP2022526028A JP2023500895A JP 2023500895 A JP2023500895 A JP 2023500895A JP 2022526028 A JP2022526028 A JP 2022526028A JP 2022526028 A JP2022526028 A JP 2022526028A JP 2023500895 A JP2023500895 A JP 2023500895A
Authority
JP
Japan
Prior art keywords
ethoxy
group
acetamide
hpyy
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526028A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021094259A5 (OSRAM
Inventor
ペーター ヴィルヘルム ハエベル
アルベルト ブレンナウアー
カルロッテ スタール マドセン
ソレン ユングバリ ペデルセン
シュテファン ペーテルス
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023500895A publication Critical patent/JP2023500895A/ja
Publication of JPWO2021094259A5 publication Critical patent/JPWO2021094259A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022526028A 2019-11-11 2020-11-09 Ｎｐｙ２受容体アゴニスト Pending JP2023500895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
EP19208394.7 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (2)

Publication Number Publication Date
JP2023500895A true JP2023500895A (ja) 2023-01-11
JPWO2021094259A5 JPWO2021094259A5 (OSRAM) 2023-02-14

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526028A Pending JP2023500895A (ja) 2019-11-11 2020-11-09 Ｎｐｙ２受容体アゴニスト

Country Status (20)

Country Link
US (3) US20210139548A1 (OSRAM)
EP (1) EP4058047A1 (OSRAM)
JP (1) JP2023500895A (OSRAM)
KR (1) KR20220100925A (OSRAM)
CN (1) CN114641303A (OSRAM)
AR (1) AR120440A1 (OSRAM)
AU (1) AU2020384729A1 (OSRAM)
CA (1) CA3156452A1 (OSRAM)
CL (1) CL2022001227A1 (OSRAM)
CO (1) CO2022006046A2 (OSRAM)
CR (1) CR20220206A (OSRAM)
DO (1) DOP2022000097A (OSRAM)
EC (1) ECSP22037660A (OSRAM)
IL (1) IL292601A (OSRAM)
JO (1) JOP20220110A1 (OSRAM)
MX (1) MX2022005661A (OSRAM)
PE (1) PE20221168A1 (OSRAM)
PH (1) PH12022551101A1 (OSRAM)
TW (1) TWI864155B (OSRAM)
WO (1) WO2021094259A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537036A (ja) * 2020-08-07 2023-08-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
CN119677527A (zh) 2022-08-18 2025-03-21 勃林格殷格翰国际有限公司 包含长效glp-1/胰高血糖素及npy2受体激动剂的组合疗法
US20240247080A1 (en) * 2022-12-21 2024-07-25 Boehringer Ingelheim International Gmbh Glp1/gip/npy2 receptor triple agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510829A (ja) * 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
JP2018522843A (ja) * 2015-06-12 2018-08-16 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
SG158141A1 (en) 2004-12-13 2010-01-29 Amylin Pharmaceuticals Inc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP1962959B1 (en) 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Neuropeptide-2 receptor-agonists
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
PL2370460T3 (pl) 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
MX2012000564A (es) 2009-07-13 2012-04-11 Zealand Pharma As Analogos de glucagon acilados.
WO2011033068A1 (en) 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EA201291234A1 (ru) 2010-06-24 2013-07-30 Зилэнд Фарма А/С Аналоги глюкагона
RU2669999C2 (ru) 2011-06-10 2018-10-17 Ново Нордиск А/С Полипептиды
US20130316941A1 (en) 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
MX356641B (es) 2012-05-03 2018-06-07 Zealand Pharma As Compuestos agonistas dobles de gip-glp-1 y procedimientos.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP2016519130A (ja) 2013-05-02 2016-06-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 治療ペプチド
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
SI3321278T1 (sl) 2013-11-14 2019-04-30 Keybioscience Ag Mimetiki kalcitonina za zdravljenje bolezni in motenj
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
JP6629198B2 (ja) * 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
PL3398961T3 (pl) 2015-12-31 2022-09-26 Hanmi Pharm. Co., Ltd. Potrójny aktywator aktywujący receptory glukagonu, glp-1 i gip
EP3452088A4 (en) 2016-05-03 2020-04-15 The Scripps Research Institute TRKB AGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
TWI865836B (zh) * 2018-11-01 2024-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510829A (ja) * 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
JP2018522843A (ja) * 2015-06-12 2018-08-16 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEPTIDES FOR YOUTH: THE PROCEDINGS OF THE 20TH AMERICAN PEPTIDE SYMPOSIUM, JPN6024008701, pages 515 - 516, ISSN: 0005473149 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537036A (ja) * 2020-08-07 2023-08-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト
JP7661478B2 (ja) 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト

Also Published As

Publication number Publication date
AR120440A1 (es) 2022-02-16
PH12022551101A1 (en) 2023-11-13
US20210139548A1 (en) 2021-05-13
US12054525B2 (en) 2024-08-06
EP4058047A1 (en) 2022-09-21
KR20220100925A (ko) 2022-07-18
CL2022001227A1 (es) 2023-02-03
MX2022005661A (es) 2022-09-07
CO2022006046A2 (es) 2022-05-20
TW202134263A (zh) 2021-09-16
WO2021094259A1 (en) 2021-05-20
AU2020384729A1 (en) 2022-04-14
CR20220206A (es) 2022-06-16
CN114641303A (zh) 2022-06-17
US20230340039A1 (en) 2023-10-26
CA3156452A1 (en) 2021-05-20
US20250002544A1 (en) 2025-01-02
JOP20220110A1 (ar) 2023-01-30
DOP2022000097A (es) 2022-06-15
ECSP22037660A (es) 2022-06-30
TWI864155B (zh) 2024-12-01
PE20221168A1 (es) 2022-07-25
IL292601A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
CN109863168B (zh) 胰淀素类似物
JP7661478B2 (ja) 可溶性ｎｐｙ２受容体アゴニスト
AU2011247452B2 (en) Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
JP6602760B2 (ja) 選択的なｐｙｙ化合物及びその使用
US12054525B2 (en) NPY2 receptor agonists
AU2016232218B2 (en) Amylin analogues
JP6701075B2 (ja) アミリン類似体
JP2017500289A (ja) ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
EA049057B1 (ru) Растворимые агонисты рецепторов npy2
EA047394B1 (ru) Агонисты рецептора npy2
JP2019189632A (ja) 選択的なｐｙｙ化合物及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023